

Daftar Pustaka

- Aalders, KC., van Bommel, AC., van Dalen, T., Sonke, GS., van Diest, PJ., Boersma, LJ., dkk., 2016. Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. *European Journal of Cancer*, **63**:118-26.
- Aapro, M., Saad, F., dan Costa, L., 2010. Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases. *The Oncologist*, **15**: 1147–58.
- Adibe, MO., Aguwa, CN., Ukwe, CV., 2013. Cost Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigeria Patient with Type 2 Diabetes, *Value Health Reg Issues*, **2(2)**:189-98.
- American Cancer Society, 2015. Breast Cancer. *American Cancer Society*.
- Andayani, T.M., 2013. *Farmakoekonomi Prinsip Dan Metodologi*. Bursa Ilmu, Yogyakarta.
- Baum, M., 2013. Modern concepts of the natural history of breast cancer: A guide to the design and publication of trials of the treatment of breast cancer. *European Journal of Cancer*, **49**: 60–4.
- Benzaid, I., Monkkonen, H., Stresing, V., Bonnelye, E., Green, J., dan Monkkonen, J., 2011. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vg9Vd2 T-cell chemotaxis and cytotoxicity in vivo. *Cancer Res*, **71**: 4562–72.
- Bland, KI., Copeland, EM., 2009. *The Breast E-Book: Comprehensive Management of Benign and Malignant Diseases*. Elsevier.
- Body, J.-J., 2003. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. *Cancer*, **97**: 859–65.
- Bootman, J., Townsend, R., dan McGhan, W., 2005. *Principle of Pharmacoeconomics*, 3rd ed. Harvey White Books Company, Cincinnati.
- Botteman, M., 2006. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. *Annals of Oncology*, **17**: 1072–82.

- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, RL., Torre, LA., Jemal, A., 2018. Global Cancer Statistic 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*, **68**(6):394-424.
- Briggs, A., Sculpher, M., dan Claxton, K., 2006. *Decision Modelling for Health Economic Evaluation*. Oxford University Press Inc, New York.
- Brufsky, A., Harker, W.G., Beck, J.T., Carroll, R., Tan-Chiu, E., Seidler, C., dkk., 2007. Zoledronic Acid Inhibits Adjuvant Letrozole-Induced Bone Loss in Postmenopausal Women With Early Breast Cancer. *Journal of Clinical Oncology*, **25**: 829–36.
- Burstein, H.J., Temin, S., Anderson, H., Buchholz, T.A., Davidson, N.E., Gelmon, K.E., dkk., 2014. Adjuvant Endocrine Therapy for Women With Hormon Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. *Journal of Clinical Oncology*, **32**: 2255–69.
- Delea, T.E., Taneja, C., Sofrygin, O., Kaura, S., dan Gnant, M., 2010. Cost-Effectiveness of Zoledronic Acid Plus Endocrine Therapy in Premenopausal Women With Hormon-Responsif Early Breast Cancer. *Clinical Breast Cancer*, **10**: 267–74.
- DeSantis, C., Ma J, Bryan, L., Jemal, A., 2014. Breast cancer statistics, 2013. *CA Cancer J Clin*, **64**(1): 52-62.
- Desen, W., 2011. Buku Ajar Onkologi Klinis, 2 nd ed. Balai Penerbit FK-UI, Jakarta
- DeVita, V.T., 2005. Principles of cancer management: Chemotherapy. In: DeVita, V.T.J, Hellman, S., Rosenberg, R.A., ed. *Cancer: principles and practice oncology 7th edition*. Philadelphia: Lippincott Williams & Wilkins.
- Dipiro, J., Talbert, R., Yee, G., Matzke, G., Wells, B., dan Posey, L., 2008. *Pharmacotherapy : A Pathophysiology Approach*, 7th ed. McGraw-Hill Companies Inc, United States of America.
- Eveline, Kezia., Purwanto, Heru., Lestari, Pudji., 2017. Faktor klinis dan histopatologi serta hubungannya dengan kekambuhan pascaoperasi pada pasien kanker payudara di RSUP dr. Soetomo, Januari-Juni 2015. *Indonesian Journal of Cancer*, **11**(2) : 55-60.
- Fenwick, E., Marshall, D., Levy, AR., Nichol, G., 2006. Using and interpreting cost effectiveness acceptability curve : an example using data from a trial of management strategies for atrial fibrillation. *BMC Health Serv Res*, **6**:52.

- Firmansyah, Rulli., Khambri, Daan., Edison, Edison., Rofinda, Z.A., 2015. Kejadian demam neutropenia pada pasien kanker payudara yang mendapat kemoterapi, *Majalah Kedokteran Andalas*, 38(1):12-9.
- Gallo, M., De Luca, M., Lamura, L., dan Normanno, N., 2011. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. *Ann Oncol*, **23**(3): 597–604.
- Gnant, M., 2011. Zoledronic acid in breast cancer: latest findings and interpretations. *Therapeutic advances in medical oncology*, **3**: 293–301.
- Gnant, M.F.X., Mlineritsch, B., Luschin-Ebengreuth, G., Grampp, S., Kaessmann, H., Schmid, M., dkk., 2007. Zoledronic Acid Prevents Cancer Treatment-Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormon-Responsif Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group. *Journal of Clinical Oncology*, **25**: 820–8.
- Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., dkk., 2009. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. *New England Journal of Medicine*, **360**: 679–91.
- Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Heck, D., Menzel, C., dkk., 2011. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. *The lancet oncology*, **12**: 631–41.
- Green, J. dan Guenther, A., 2011. The backbone of progress—preclinical studies and innovations with zoledronic acid. *Crit Rev Oncol Hematol*, **77**(1):S3-S12 .
- Guise, Theresa A., 2013. Breast Cancer Bone Metastases: It’s All about the Neighborhood, *Cell*, **154**: 957-9.
- Hadji, P., Frank, M., Jakob, A., dan Siebers, J.W., 2013. Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: Retrospective analysis results in an unselected single-center cohort. *Journal of Bone Oncology*, **2**: 2–10.
- Harlow, Sioban D., 2012. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause: *The Journal of The North American Menopause Society*, **19**(4):387-95.

- Hortobagyi, GN., Zheng, Ming., Mohanlal, Ramon., 2019. Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Time Dosing. *The Oncologist*, **24**(2):178-84.
- Irwan, Irwan., Azamris, Azamris., Bachtiar, Hafni., 2015. Perbandingan prognosis subtype molekuler kanker payudara antara pasien kanker payudara wanita usia muda dan tua di RSUP dr. M. Djamil Padang, *Majalah Kedokteran Andalas*, **38** (3): 208-17.
- Kavanagh, K., Guo, K., Dunford, J., Wu, X., Knapp, S., dan Ebetino, F., 2006. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. *Proc Natl Acad Sci USA*, **103**: 7829–34.
- Kementerian Kesehatan RI, 2013. Keputusan Menteri Kesehatan Republik Indonesia Nomor 328/Menkes/SK/VIII/2013 tentang Formularium Nasional, Jakarta.
- Kementerian Kesehatan RI, 2015a. Stop Kanker. *Infodatin : Pusat Data Dan Informasi Kementerian Kesehatan RI*. Jakarta.
- Kementerian Kesehatan RI, 2015b. *Panduan Nasional Penanganan Kanker : Kanker Payudara*. Jakarta.
- Kementerian Kesehatan RI, 2015c. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK 02.02/Menkes/523/2015 tentang Formularium Nasional, Jakarta.
- Kementerian Kesehatan RI, 2016a. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK 02.02/Menkes/137/2016 tentang Perubahan atas Keputusan Menteri Kesehatan Nomor HK 02.02/Menkes/523/2015 tentang Formularium Nasional, Jakarta.
- Kementerian Kesehatan RI, 2016b. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK 02.02/Menkes/636/2016 tentang Perubahan kedua atas Keputusan Menteri Kesehatan Nomor HK 02.02/Menkes/523/2015 tentang Formularium Nasional, Jakarta.
- Kementerian Kesehatan RI, 2017. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK 01.07/Menkes/659/2017 tentang Formularium Nasional, Jakarta.
- Kementerian Kesehatan RI, 2018. Hasil utama Riskesdas 2018. Badan Penelitian dan Pengembangan Kesehatan, Jakarta.

- Kennecke, Hagen., Yerushalmi, Rinat., Woods, Ryan., Cheang, M.C.U., Voduc, David., Speers, C.H., dkk., 2010. Metastatic Behavior of Breast Cancer Subtypes, *J Clin Oncol*, **28**: 3271-7.
- Khoiriyah, SD., dan Lestari, Keri., 2018. Review Artikel : Kajian Farmakoekonomi yang Mendasari Pemilihan Pengobatan di Indonesia, *Farmaka*, **16**(3) : 134-45.
- Kyvernitakis, Ioannis., Kann, PH., Thomasius, F., Hars, Olaf., Hadji, P., 2018. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid : final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial, *Bone*, **114**:109-15.
- Kljin JG, Blamey B, Tominaga T, Duchateau L, Sylvester R, dkk., 2001. Combined tamoxifen and luteinizinghormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. *J Clin Oncol*, **19**:343-53.
- Logman, J.F.S., Heeg, B.M.S., Botteman, M.F., Kaura, S., dan van Hout, B.A., 2010. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. *Annals of Oncology*, **21**: 1529–36.
- Mavroudis, D., Alexopoulos, A., Malamos, N., Ardavanis, A., Kandylis, C., Stavrinidis, R., dkk., 2003. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin, *Oncology*, **64**:2017-12.
- McPherson, K., Steel, C., dan Dixon, J., 2000. Breast cancer-Epidemiology, Risk factor, and Genetics. *British Medical Journal*, **321**: 624–28.
- NCCN, 2016. Clinical Practice Guideline in Oncology Breast Cancer, Version 1. 2016, National Comprehensive Cancer Network, Inc.
- O’Shaughnessy J., 2005. Extending Survival with Chemotherapy in Metastatic Breast Cancer. *The Oncologist*, **10**(S3):20-29.
- Overgaard, Marie., Hansen, PS., Overgaard, Jens., Rose, Carsten., Andersson, M., Bach, Flemming., dkk., 1997. Post-operative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy, *N Engl J Med*, **337**:949-55.

- Paik, Soonmyung., Shak, Steven., Tang, Gong., Kim, Chungyeul., Baker, Joffre., Cronin, Maureen., dkk., 2004. A Multigene assay to predict recurrence of tamoxifen-treated, node negative breast cancer, *N Engl J Med*, **351**: 2817-26.
- Piccart-Gebhart, MJ., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, *N Engl J Med*, **353**(16):1659-72.
- Proverawati, Atikah. 2010. Menopause dan Sindrom Pre Menopause. Yogyakarta: Muha Medika
- Purnamasari, Vina., Andayani, T.A., Fudholi, Achmad., Analisis biaya terapi pada pasien kanker payudara dengan terapi hormon, *Jurnal Manajemen dan Pelayanan Farmasi*, **5**(1): 1-7.
- Rabin, R. dan Charro, F., 2001, EQ-SD: a Measure of Health Status from the EuroQol Group, *Ann Med*, **33**, 337-43.
- Ragaz, Joseph., Jackson, SM., Plenderleith, IH., Spinelli, JJ., Basco, VE., Wilson, KS., dkk., 1997. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer, *N Engl J Med*, **337**:956-62.
- Reenen, M. dan Janssen, B., 2015, EQ-5D-5L User guide: Basic Information on How to Use the EQ-5D-5L Instrument, EuroQol Group.
- Rogers, MJ., Crockett, JC., Coxon, FP., Mönkkönen, J., 2011. Biochemical and molecular mechanisms of action of bisphosphonates. *Bone*, **49**:34-41.
- Rosary, Rosary., Sjakti, Hikari A., 2010. Penggunaan granulocyte colony-stimulating factor pada pasien tumor padat yang mengalami neutropenia, *Sari Pediatri*, **11**(6):428-33.
- Russell, R., 2007. Bisphosphonates: mode of action and pharmacology. *Pediatrics*, **119**: S150–S162.
- Sanchez, L., 2008. *Pharmacoeconomic : Principles, Methods and Application in Pharmacotherapy A Pathophysiologic Approach*, 6th ed. McGraw-Hill Companies Inc, New York.
- Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., dkk., 2015. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **26**: 8–30.

- Siahaan, Irwan H., Tobing, Tina C., Rosdiana, Nelly., Lubis, Bidasari., 2007. Dampak Kardiotoxic Obat Kemoterapi Golongan Antrasiklin, *Sari Pediatri*, **9**(2):151-156.
- Soares, MO., Canto e Castro, L., 2010. Simulation or cohort models? Continuous time simulation and discretized Markov model to estimate cost effectiveness. *CHE Res Pap*, **56**:1-20.
- Suzuki, K., Sun, R., Origuchi, M., Kanehira, M., Takahata, T., dan Itoh, J., 2011. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. *Mol Med*, **17**: 579–87.
- Tantai, N., Chaikledkaew, U., Tanwandee, T., Werayingyong, P., Teerawattananon, Y., 2014. A Cost Utility Analysis of Drug Treatments In Patients with HBeAg-positive Chronic Hepatitis B in Thailand, *Health Serv Res*, **14**(170):1–13.
- Takeuchi, H., Muto, Y., Tashiro, H., 2009. Clinicopathological characteristics of recurrence more than 10 years after surgery in patients with breast carcinoma. *International Institute of Anticancer Research*, **29**(8):3445-8.
- Thavorncharoensap, M., 2014. Measurement of Utility. *J Med Assoc Thai*, **97**: S43–S49.
- Tinker, A., 1997. Safe Motherhood as an Economic and Social Investment. Presentation at Safe Motherhood Technical Consultation in Sri Lanka.
- Vogenberg, F., 2001. *Introduction to Applied Pharmacoeconomics*. McGraw-Hill, United States of America.
- Wahyuni, Fatma S., Windrasari, Wessi., Khambri, Daan., 2018. Evaluasi Terapi Adjuvant Hormonal dan Hubungannya Terhadap Outcome Klinis Pasien Kanker Payudara Stadium Dini di Kota Padang, *Jurnal Sains Farmasi & Klinis*, **5**(3):176-84.
- Walley, T., Haycox, A., dan Boland, A., 2004. *Pharmacoeconomics*. Elsevier Science Limited, Spain.
- Wang, Y., Atkins, D., Foekens, A.J., dan Klijn, G.M.J., 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, *The Lancet*, **365**: 1687–1717.

- WHO-CHOICE., 2003. Making choices in health : WHO guide to cost-effectiveness analysis. Glob Program Evid Heal Policy, World Heal Organ Geneva, Available from : https://www.who.int/choice/publications/p_2003_generalised_cea.pdf
- WHO., 2017. Global Health Observatory data repository : Life tables by country, Available from : <http://apps.who.int/gho/data/?theme=main&vid=60750>
- Winter, M., Holen, I., dan Coleman, R., 2008. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. *Cancer Treat Rev*, **34**: 453–75.
- Wulansari, Hesti., Andayani, T.A., W, Nurcahyanti., 2013. Analisis biaya terapi dan gambaran pengobatan pada pasien kanker payudara di instalasi rawat inap RSUD dr. Moewardi di Surakarta pada tahun 2011, Skripsi. Fakultas Farmasi. Universitas Muhammadiyah Surakarta : Surakarta.



UNIVERSITAS
GADJAH MADA

Cost Utility Analysis Penggunaan Asam Zoledronat Pada Pasien Premenopausal Early Breast Cancer Dengan Hormon Responsif

FEF RUKMININGSIH, Dr. Tri Murti Andayani, Sp.FRS., Apt ; Dr. Fita Rahmawati, Sp.FRS., Apt ; dr. Kartika Widayati.

Universitas Gadjah Mada, 2019 | Diunduh dari <http://etd.repository.ugm.ac.id/>